Risk of cardiovascular disease in elderly subjects with obesity and liver fibrosis and the potential benefit of statin treatment.

ABSTRACT:

Background

Liver fibrosis progression is influenced by older age and cardiometabolic risk factors such as obesity and is associated with an increased risk of cardiovascular events. While statins may protect against cardiovascular complications, their effects in elderly individuals with obesity and liver fibrosis are unclear.

Method

The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) database was used to evaluate the effect of pravastatin on major adverse cardiovascular events in an elderly population (>70 years). Subjects were categorized by BMI: lean (<25 kg/m²), overweight (25-29.9 kg/m²) and obese (≥30 kg/m²). Liver fibrosis was assessed using the FIB-4 index: low risk (<2.0), intermediate risk (2.0-2.66) and high risk (≥

SUBMITTER: Theel WB 

PROVIDER: S-EPMC11810556 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature